1. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6

2. Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1):e000417. doi:10.1136/bmjgast-2020-000417

3. Cheung K.S., Hung I. F., Chan P. P. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. -2020 Apr 3: S0016-5085(20)30448-0. doi: 10.1053/j.gastro.2020.03.065.

4. Sultan S., Altayar O., Siddique S. M. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. - 2020. -May 11: S0016-5085(20)30593-X. doi: 10.1053/j.gastro.2020.05.001.

5. Parasa S, Desai M, Th oguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(6):e2011335. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.11335

6. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;(29):7-15. doi:10.1093/oxfordjournals.jncimonographs.a003443

7. Захаров А.А., Ильна Н. А. Анализ микрофлоры ротовой полости обследованных людей с различными заболеваниями // Успехи современного естествознания. - 2007, № 12 (приложение, часть 3). - С. 141-143.

8. AADR PRESS RELEASES. Journal of Dental Research Systematic Analysis Examines Global Burden of Oral Conditions. Available at: https://www.iadr.org/AADR/About-Us/News/ArtMID/134369/ArticleID/338/Journal-of-Dental-Research-Systematic-Analysis-Examines-Global-Burden-of-Oral-Conditions (Monday, March 20, 2017)

9. Risk Factors. Available at: https://www.fdiworlddental.org/oral-health/risk-factors. [Accessed 10 August 2020].

10. Xu H., Zhong L., Deng J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. - 2020. - Vol. 12, Iss. 8

11. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24(4):1619-1621. doi:10.1007/s00784-020-03248-x

12. Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020;26(8):1920-1922. doi:10.3201/eid2608.200681

13. Arimura H. Effect of lysozyme from human placenta on ectromelia virus. Acta Virol. 1973;17(2):130-137.

14. Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mo-sapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121-124.

15. Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter Pylori заболеваний VI Московские соглашения. Экспериментальная и клиническая гастроэнтерология. - 2017. - № 138 (2). - С. 3-21.

16. Ивашкин В.Т., Маев И. В., Трухманов А. С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальнойрефлюксной болезни. Рос журнгастроэнтеролгепатолколопроктол. - 2017. -№ 27(4). - С. 75-95.

17. Гриневич В.Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. - 2020. - № 176 (4). DOI:10.31146/1682-8658-ecg-176-4

18. Временные методические рекомендации МЗ РФ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020). - 165 c.

19. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. Published 2019 May 8. doi:10.1371/journal.pone.0216750

20. Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. - 2017. - Vol. 3(11): eaao4966. Published 2017 Nov 15. doi:10.1126/sciadv.aao4966.

21. World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics'. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiot-ics-and-prebiotics-english [Accessed 10 August 2020].

22. Гриневич, В. Б. Пребиотическая коррекция микробно-тканевого комплекса кишечника, как базовая составляющая современной патогенетической терапии метаболического синдрома и ассоциированных кардиоваскулярных и цереброваскулярных заболеваний. Учебно-методическое пособие / В. Б. Гриневич, Е. И. Сас, В. Е. Кон [и др.]. - СПб., 2012. - 20 с.

23. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?. Aliment Pharmacol Ther. 2005;22(2):79-94. doi:10.1111/j.1365-2036.2005.02531.x

24. Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-916. doi:10.5009/gnl15537

25. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393-3398. doi:10.1007/s10620-010-1166-9

26. Wen X., Chen X., Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. 2009;34(5):457-160.

27. Yasuda T, Chiba H, Satomi T, et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4):e3. Published 2012 Jan 1. doi:10.5037/jomr.2011.2403

28. Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2

29. Jiang G, Cai Y, Yi X, et al. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study [published online ahead of print, 2020 May 12]. J Med Virol. 2020;10.1002/jmv.25998. doi:10.1002/jmv.25998

30. Lechien JR, Bartaire E, Bobin F, Hans S, Saussez S. The association between laryngopharyngeal reflux and COVID-19 is still not demonstrated [published online ahead of print, 2020 May 28]. J Med Virol. 2020; doi:10.1002/jmv.26080

31. Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 Suppl 1:55-62. doi:10.1046/j.1365-2036.18.s1.6.x

32. Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;329:40-47. doi:10.1016/j.taap.2017.05.012

33. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi:10.1007/s10620-017-4871-9

34. Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259-263. doi:10.1089/jop.2011.0142

35. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of re-bamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi:10.2165/00126839-200304010-00002

36. Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журнгастроэнтеролгепатолколо-проктол. - 2019. - Т. 29, № 5. - С. 53-74. https://doi.org/10.22416/1382-4376-2019-29-5-53-74

37. Мартынов А. И., Шептулин А. А., Маев И. В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Рос журнгастроэнтеролгепатолколопроктол. - 2020. Т. 30, № 2. - С. 7-14. https://doi.org/10.22416/1382-4376-2020-30-2-7-14

38. Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacterpylori у взрослых. Рос журнгастроэнтеролгепатолколопроктол. - 2018. - Т. 28, № 1. - С. 55-70. https://doi.org/10.22416/1382-4376-2018-28-1-55-70

39. Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. doi:10.1159/000452356

40. Simadibrata M. et al. Anti free radical &anti inflammatory effect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013, - Vol. 3, pp. 72-77.

41. Hayashi S, Sugiyama T, Amano K, et al. Effect of re-bamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. doi:10.1128/AAC.42.8.1895

42. Симаненков В. И., Бакулина Н. В., Филь Т. С., Хубиева А. Х. Оценка эффективности эрадикации Н. Pylori при добавлении к схеме лечения цитопро-тективного препарата ребамипид: результаты исследования Бастион. Фарматека. - 2017. - S5. - C. 65-70.

43. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. Published 2019 Sep 19. doi:10.3390/jcm8091498

44. Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Лечение инфекции Helicobacterpylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Рос журнгастроэнтеролгепатолколопроктол. - 2017. - Т. 27, № 4. - С. 4-21.

45. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X

46. Xia L., Wu K. Gastroenterology Practice in COVID-19 Epidemic. World Gastroenterology News. May 2020. pp. 7-10

47. Consensus of Diagnosis and Treatment of digestive disorders related to COVID-19. Natl Med J Chin. - 2020. - Vol. 40: E001. Published Online

48. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-2332. doi:10.3748/wjg.v26.i19.2323

49. Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. -2018. - № 56. - С. 1-29.

50. Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. - 2018. - № 151(03). - С. 04-18.

51. Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2

52. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518-1519. doi:10.1053/j.gastro.2020.02.054

53. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J Hepatol. - 2020; S0168-8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006

54. Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewarticle/926628

55. Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. doi: 10.1111/LIV.14470

56. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6. doi:10.1016/j.cell.2020.02.058

57. Chai X., Hu L., Zhang Y. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. 02.03.931766.

58. Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-1796. doi:10.1136/gut.2004.062398

59. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113

60. Fan Z., Chen L., Li J., Tian C., Zhang Y., Huang S. et al. Clinical Features of COVID-19-Related Liver Damage. -2020. Available at SSRN3546077. DOI: 10.2139/ssrn.3546077.

61. Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507-13.

62. Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144-1145. doi:10.1136/gutjnl-2020-321051

63. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

64. Guan W. J., Ni Z.Y, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020; NEJMoa2002032. doi:10.1056/NEJMoa2002032

65. Albillos A., Lario M., Alvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385-1396.

66. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X

67. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001

68. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0

69. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. doi:10.1111/liv.14435

70. Zhang C., Shi L., Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper 17

71. Gao F. et al. Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic PatientsJ Gastroenterol Hepatol. - 2020. doi: 10.1111/jgh.15112.

72. Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705-708. doi:10.1016/j.jhep.2020.05.013

73. Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi:10.1056/NEJMp2003539

74. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451-458. doi:10.4065/mcp.2009.0534

75. Маевская М. В., Надинская М. Ю., Луньков В. Д. и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2019. - Т. 29(6). - С. 22-29.

76. Mroz MS, Harvey BJ. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids. 2019;151:108461. doi:10.1016/j.steroids.2019.108461

77. Schultz F, Hasan A, Alvarez-Laviada A, et al. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. Prog Biophys Mol Biol. 2016;120(1-3):149-163. doi:10.1016/j.pbiomolbio.2016.01.003

78. Işık S, Karaman M, Qilaker Micili S, et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017;45(4):339-349. doi:10.1016/j.aller.2016.12.003

79. Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019;234(11):20057-20065. doi:10.1002/jcp.28602

80. Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published 2020 Jun 19. doi:10.3390/vaccines8020320

81. Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm [published online ahead of print, 2020 May 30]. Med Hypotheses. 2020;143:109897. doi:10.1016/j.mehy.2020.109897

82. Hoff mann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell - 2020. - Vol. 181. - P. 271-280.

83. Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. - 2020. -Vol. 5. - P. 562-569.

84. Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. - 2020. - Vol. 69(6). - P. 997-1001. doi: 10.1136/gutjnl-2020-321013.

85. Estes M. K. G., Knipe D. M., Howley P. M. et al. Rotaviruses, in Fields Virology (Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013), 6th ed., pp. 1347-1401.

86. Zang R., Gomez Castro M. F., McCune B.T. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. - 2020. - Vol. 5(47): eabc3582. doi:10.1126/sciimmunol.abc3582

87. Marild K., Fredlund H., Ludvigsson J. F. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. The American journal of gastroenterology. - 2010. - Vol. 105(11). - P. 2465-2473

88. Di Sabatino A. Is it worth investigating splenic function in patients with celiac disease? World journal of gastroenterology: WJG. - 2013. - Vol. 19(15). - P. 2313

89. Altamimi E. Effect of COVID-19 Pandemic and Lockdown on Children With Gastrointestinal Disorders // Gastroenterology Research. - 2020

90. Al-Toma A., Volta U., Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. - 2019 - Vol. 7(5). -P. 583-613. doi: 10.1177/2050640619844125.

91. Лазебник Л. Б., Ткаченко Е. И., Орешко Л. С. и др. рекомендации по диагностике и лечению целиакии взрослых Экспериментальная и клиническая гастроэнтерология - 2015. - № 117 (5). - Р. 3-12

92. Siniscalchi M. et al. COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine: COVID-19 and CeD // Digestive and Liver Disease. - 2020

93. Lee A. R. Telehealth Counseling for Patients with Celiac Disease During COVID-19 //Gastroint Hepatol Dig Dis. - 2020. - Т. 3. - № . 1. - С. 1-2.

94. Ивашкин В. Т., Шелыгин Ю. А. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. - 2017. - № 2. - С. 7-29.

95. Goldstein J. L., Eisen G. M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment PharmacolTher. - 2007. - Vol. 15; 25(10). - P. 1211-22.

96. Washio E., Esaki M., Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal AntiInflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. - 2016. Vol. 14(6). - P. 809-15.

97. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate to severe small intestinal damage. PLoS One. - 2015. - Vol. 10(4): e0122330

98. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. - 2013. - Vol. 58(7). - P. 1991-2000.

99. Massironi S., Vigano C., Dioscoridi L. et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol. -2020 May 29: S1542-3565(20)30752-7. doi: 10.1016/j.cgh.2020.05.045.

100. Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. - 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018.

101. Toskes P. Bacterial overgrowth of the gastrointestinal tract // Adv. Int. Med. 1993. Vol. 38. P. 387-407

102. Маев И. В., Кучерявый Ю. А., Андреев Д. Н., Ивашкина Н. Ю. Синдром избыточного бактериального роста в тонкой кишке: клиническое значение, критерии диагностики и терапевтическая тактика. Инфекционные болезни: новости, мнения, обучение. - 2016. - № 3. - С. 118-125

103. Lauritano E. C., Gabrielli M., Lupascu A. et al. Rifaximin dosefinding study for the treatment of small intestinal bacterial overgrowth // Aliment. Pharmacol. Ther. - 2005. - Vol. 22. - P. 31-35.

104. Cuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin // Minerva Gastroenterol. Dietol. - 2006. - Vol. 52. - P. 89-95.

105. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055.

106. Pan L., Mu M., Ren H. G. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. - 2020. DOI: 10.14309/ajg.0000000000000620.

107. Ивашкин В. Т. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журнгастроэнтеролгепатолколопроктол. - 2017. - Т. 27(5). - С. 76-93. DOI: 10.22416/1382-4376-2017-27-5-76-93.

108. Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. Published 2020 Mar 6. doi:10.3390/ijerph17051729

109. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert RevGastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70. DOI:10.1586/egh.10.25.38-41

110. Zhou Q., Verne M. L., Fields J. Z. et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002.

111. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70.

112. Song D. U., Ryu M. H., Chay K. O. et al. Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-52.

113. Suzuki T., Yoshida N., Nakabe N. et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77.

114. Парфенов А. И., Быкова С. В., Сабельникова Е. А. идр. Энтеропатия с нарушенным перевариванием мембран и ребамипидом. Консилиум Медикум. -2019. - Т. 21 (8). -С. 49-57. DOI: 10.26442/20751753.2019.8.190504

115. Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A CrossSectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019;25(6):623-636.

116. Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. - 2019. Jun 26: e13385. doi: 10.1111/ijcp.13385.

117. Menees S. B., Maneerattannaporn M., Kim H. M., Chey W. D. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012 Jan; 107(1):28-35

118. Anand S., Mande S. S. Diet, Microbiota and Gut-Lung Connection. Front Microbiol. 2018;(9):2147. doi: 10.3389/fmicb.2018.02147.

119. Trompette A., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014;20 (2):159-166.

120. Samuelson D. R., Welsh D. A., Shellito J. E. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015. 2015;(6):1085.. doi: 10.3389/fmicb.2015.01085.

121. Nikolaou E., Kamilari E., Savkov D. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. World J Pediatr. 2020;16(2):168-176. doi: 10.1007/s12519-019-00315-6.

122. Pinto-Cardoso S., Klatt N. R., Reyes-Teran G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. CurrOpin HIV AIDS. 2018;13(1):53-60. doi: 10.1097/COH.0000000000000428.

123. Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571-575. doi: 10.4161/gmic.32130.

124. Otani K., Tanigawa T., Watanabe T. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 2017;95:22-28. doi: 10.1159/000452356

125. Jang H., Park S., Lee J. et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018;33(4):878-886. doi:10.1111/jgh.14021

126. Rahier J. F., Magro F., Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;(8):443-468.

127. Al-Ani A. H., Prentice R. E., Rentsch C. A. et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment PharmacolTher. -2020. - Apr 29:10.1111/apt.15779. Doi: 10.1111/apt.15779.

128. Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 20, 2020

129. Ивашкин В. Т., Шелыгин Ю. А. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017. - № 1(59). - С. 6-30.

130. Samanta J., Dhar J., Khaliq A., Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-18. DOI: 10.1055/s-0040-1712077

131. Kennedy N. A., Jones G. R., Lamb C. A., et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. doi:10.1136/gut-jnl-2020-321244

132. Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic American Gastroenterological Association. https://gastro.org/practice-guidance/practice-updates/covid-19/gastroenterology-professional-society-guidance-on-en-doscopic-procedures-during-the-covid-19-pandemic/ Accessed June 06, 2020.

133. Rubin D. T., Abreu M. T., Rai V., Siegel C. A. On behalf of the International Organization for the Study of Inflammatory Bowel Disease, Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. - 2020, doi: https://doi.org/10.1053/j.gastro.2020.04.002.

134. RAND PANEL STATEMENTS Patients with COVID-19 Crohn's Disease and COVID-19 Ulcerative Colitis. IOIBD Update on COVID19 for Patients with Crohn's Disease and Ulcerative Colitis https://ioibd.org/wp-content/uploads/2020/05/RAND-PANEL-STATEMENTS.pdf

135. Временные рекомендации по ведению больных COVID-19 и эндокринными заболеваниями / Под ред. Гринева Е. Н., Халимова Ю. Ш., Бабенко А. Ю. и др. - Медицинской Ассоциацией Эндокринологов Санкт-Петербурга, 2020 г. - 9 с.

136. Ивашкин В. Т., Шептулин А. А., Зольникова О. Ю. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения // Российский журнал гастроэнтерологии, гепатологии и колопроктоло-гии 2020 30(2) - 7 https: //doi.org/10.22416/138243712020-30-3-7.

137. Szatmary P., Arora A., Raraty M. G. T. et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. - 2020. doi.org/10.1053/j.gastro.2020.05.069.

138. Bruno G., Fabrizio C., Santoro C. R., Buccoliero G. B. Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence [published online ahead of print, 2020 Jun 4]. J Med Virol. -2020;10.1002/jmv.26134. doi:10.1002/jmv.26134

139. Временные методические рекомендации. Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19) // Драпкина О. М., Маев И. В., Бакулин И. Г. и др. -Москва, 2020. - 68 с.

140. Клинические Рекомендации Российского Общества Хирургов, Ассоциации гепатопанкреатобилиарных хирургов стран СНГ «Острый панкреатит» - М., 2015. - 38 с.

141. Рекомендации Научного Общества Гастроэнтерологов по диагностике и лечению хронического панкреатита (приняты Псъездом НОГР 2 марта 2011 на заседании Российского панкреатологического клуба// Экспериментальная и клиническая медицина. - 2011. - № 7. - С. 122-129.

142. Российский консенсус по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Абдулхаков С. Р. и соавт.// Терапевтический архив. - 2017. - № 2. - С. 105-113. doi: 10.17116/terarkh2017892105-113.

143. Хатьков И. Е. Спорные вопросы российского консенсуса по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А., Гриневич В. Б. //Альманах клинической медицины. - 2016. -Т. 44., № 6. - С. 654-660.

144. Ивашкин В. Т., Маев И. В., Охлобыстин А. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72-100.

145. Клинические Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению хронического панкреатита / Под ред. Ивашкина В. Т., Маева И. В., Шифрина О. С. и др. - М., 2014. -45с.

146. Хатьков И. Е. Российский консенсус по диагностике и лечению хронического панкреатита: акцент на нутритивный статус и вопросы питания. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А. и соавт.// Фарматека. - 2016; Гастроэнтерология/гепатология. - С. 27-32.

147. Клинические Рекомендации Российской Ассоциации Эндокринологов «Алгоритмы Специализированной Медицинской Помощи больным Сахарным Диабетом» / Под ред. Дедова И. И., Шестаковой М. В., Майрова А. Ю. - М., 2017. - 111 с.

148. В. Т. Ивашкин, И. В. Маев, П. В. Царьков и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по Диагностике и лечению язвенной болезни у взрослых. 2020

149. Diaz J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3): taaa041. doi:10.1093/jtm/taaa041.

150. Zheng Y. Y., Ma Y. T., Zhang J. Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5.

151. Abassi Z., Assady S., Khoury E. E., Heyman S. N. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. Am J Physiol Heart Circ Physiol. 2020; 318(5): H1080-H1083. doi:10.1152/ajpheart.00215.2020.

152. Vaduganathan M., Vardeny O., Michel T., McMurray J. V, Pfeffer M. A, Solomon S. D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760.

153. Gheblawi M., Wang K., Viveiros A., et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015.

154. South A. M., Diz D. I., Chappell M. C. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084-H1090. doi:10.1152/ajpheart.00217.2020.

155. Ferrario C. M, Jessup J., Chappell M. C. et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-10.

156. Burchill L. J, Velkoska E., Dean R.G, Griggs K., Patel S. K., Burrell L. M. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-58.

157. Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensinconverting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28: 15-21.

158. Halliday B. P., Wassall R., Lota A. S., et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393: 61-73.

159. Mehta N., Kalra A, Nowacki A. S., et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; e201855. doi:10.1001/jamacardio.2020.1855.

160. Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; doi:10.1056/NEJMoa2006923.

161. Tadic M., Cuspid C., Mancia G., Dell'Oro R., Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacological research, vol. 158 104906. 13 May. 2020, doi:10.1016/j.phrs.2020.104906.

162. Jeffrey K. Aronson, Robin E. Ferner. Drugs and the renin-angiotensin system in covid-19. Clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. BMJ 2020;369: m1313 doi: 10.1136/bmj.m1313 (Published 2 April 2020) Page 2.

163. Aronson J. K., Ferner R. E., с Drugs and the renin-angiotensin system in covid-19. BMJ. 2020;369: m1313. Published 2020 Apr 2. doi:10.1136/bmj.m1313

164. Wang T. D. Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators. Acta Cardiol Sin. 2020;36(3):179-182. doi:10.6515/ACS.202005_36(3).20200430A.

165. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика // 2019;18(1):5-66 http://dx.doi.org/10.15829/1728-8800-2019-1-5-66

166. Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? Journal of Hypertension. 2019;(37):1574-1586. DOI:10.1097/HJH.0000000000002088.

167. Wade D. T. Rehabilitation after COVID-19: an evidence-based approach [published online ahead of print, 2020 Jun 9]. Clin Med (Lond). 2020; clinmed.2020-0353. doi:10.7861/clinmed.2020-0353]. De Biase S,

168. Cook L, Skelton D. A., Witham M, Ten Hove R. The COVID-19 Rehabilitation Pandemic [published online ahead of print, 2020 May 29]. Age Ageing. 2020; afaa118. doi:10.1093/ageing/afaa118

169. Lopez M., Bell K., Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Non-Pulmonary Manifestations and Complications [published online ahead of print, 2020 May 26]. Am J Phys Med Rehabil. 2020;doi:10.1097/PHM.0000000000001479

170. Wang F., Wang H., Fan J. et al. Pancreatic injury patterns in patients with COVID-19 pneumonia [published online ahead of print, 2020 Apr 1]. Gastroenterology. 2020;. doi:10.1053/j.gastro.2020.03.055

171. Han C., Duan C., Zhang S. et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes [published online ahead of print, 2020 Apr 15]. Am J Gastroenterol. 2020; doi:10.14309/ajg.0000000000000664

172. Ling Y., Xu S. B., Lin Y. X. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients [published online ahead of print, 2020 Feb 28]. Chin Med J (Engl). 2020; doi:10.1097/CM9.0000000000000774

173. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment PharmacolTher. 2020;51(9):843-851. doi:10.1111/apt.15731

174. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J ChinMedAssoc. 2020;83(6):521-523. doi:10.1097/JCMA.0000000000000319

175. Thachil J et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. published: 25 March 25, 2020

176. Hunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020 https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf

177. Gris J. C. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. https://doi.org/10.1016/j.accpm.2020.04.013

178. Wade D. T. What is rehabilitation? An empirical investigation leading to an evidence-based description. Clin Rehabil. 2020;34(5):571-583. doi:10.1177/0269215520905112

179. Infusino F., Marazzato M., Mancone M. et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020;12(6):E.1718. Published 2020 Jun 8. doi:10.3390/nu12061718

180. Крюков, А. Е. Особенности кишечного микробиоценоза у лиц молодого возраста с внебольничной пневмонией: автореф. дис. ... канд. мед. наук: 14.00.05 / Крюков Александр Евгеньевич. - СПб., 2006. - 27 с.

181. Almario C. V., Chey W. D., Spiegel B. M. R. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. - 2020 (pre-print posted online July 7, 2020)

182. Camilleri M., Oduyebo I., Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unansweredquestions. Am J Physiol Gastrointest Liver Physiol.2016;311(5):777-784. doi: 10,.1152/ajpgi.00242.2016.

183. Ng Q. X., Soh A. Y. S., Loke W., Lim D. Y., Yeo W. S. The role of inflammation inirritable bowel syndrome (IBS).J Inflamm Res.2018;11:345 doi:10.214/JIR.S174982.

184. Самсонов А. А., Андреев Д. Н., Дичева Д. Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека.2014;(18):7-14. Режим доступа: https://www.elibrary.ru/item.asp?id=22474321.

185. Christopher H. Blevins et al. The Esophageal Epithelial Barrier in Health and Disease Clinical Gastroenterology and Hepatology 2018;16:608-617 https://doi.org/10.1016/j.cgh.2017.06.035

186. В. Т. Ивашкин, А. С. Трухманов, М. И. Гоник. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни ТЕРАПЕВТИЧЕСКИЙ АРХИВ 4, 2020 DOI:10.26442/00403660.2020.04.000568

187. Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Reflux Disease, Including Non-Erosive Reflux Disease: A Multi-Center, Randomized, Single-Blind, Placebo-Controlled Study AGA Abstracts May 2019 Volume 156, Issue 6, Supplement 1, Page S-5

188. SuJin Hong et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study Gut Liver. 2016 Nov; 10(6): 910-916.

189. Gweon T. G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50.

190. Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015;17(6):24. doi:10.1007/s11894-015-0452-2

191. Yu. M. Stepanov et al. Determination of intercellular contacts in patients with irritable bowel syndrome Gastroenterologia. 2019;53(2):128-131. doi: 10.22141/2308-2097.53.2.2019.168987

192. Fukui H.: Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? InflammIntest Dis 2016;1:135-145. doi: 10.1159/000447252

193. Л. Б. Лазебник, Е. В. Голованова, проф. С. А. Алексеенко и др. Российский консенсус «Гипераммониемии у взрослых» Утвержден в качестве документа Российского научного медицинского общества терапевтов (РНМОТ) и Научного общества гастроэнтерологов России (НОГР) 20-21 ноября 2019 г. XIV Национальным конгрессом терапевтов и XXII съездом НОГР. Терапия, 2020, № 4, 26-51 DOI: https://dx.doi.org/10.18565/therapy.2020.4.36-51

194. Максимов В. А., Торшин И. Ю., Чучалин А. Г. и др. Эффективность и безопасность полипептидного препарата (лаеннек) в терапии COVID-19, Экспериментальная и клиническая гастроэнтерология. 2020, 6 (178) 55-63 DOI: 10.31146/1682-8658-ecg-178-6-55-63

195. Saigal S. et al. Применение адеметионина у пациентов с заболеваниями печени: обзор Int J Res Med Sci. 2019 Jun;7(6):2482-2493, DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192550

196. Openshaw P. J. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100-102. doi: 10.1038/mi.2008.79.

197. Zuo T, Zhang F, Lui GCY, Yeoh YK, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 May 19: S0016-5085(20)34701-6. doi: 10.1053/j.gastro.2020.05.048.

198. Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza. Clin Infect Dis. 2020 Jun 4: ciaa709. doi: 10.1093/cid/ciaa709.

199. Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. 2020 May 13;285:198018. doi: 10.1016/j.virusres.2020.198018.

200. Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieёrs G, Guery B, Delhaes L. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and InterKingdom Crosstalks. Front Cell Infect Microbiol. 2020 Feb 19;10:9. doi: 10.3389/fcimb.2020.00009.

201. Tang L, Gu S, Gong Y, Li B, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. doi: 10.1016/j.eng.2020.05.013.

202. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. doi: 10.1164/rc-cm.200912-1853OC.

203. Zeng J, Wang CT, Zhang FS, Qi F, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016 Jun;42(6):1018-28. doi: 10.1007/s00134-016-4303-x.

204. Di Renzo L, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4062-4063. doi: 10.26355/eur-rev_202004_20977.

205. Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health. 2020 May 8;8:186. doi: 10.3389/fpubh.2020.00186.

206. Sarkar P, Borah S, Sharma HK. Can microbial SCFA, Butyrate be the alternate Savior against COVID-19?, Curr. Trends Pharm. Res., 2020, 7 (1): 11-14.

207. d'Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020 Jul 7;7:389. doi: 10.3389/fmed.2020.00389.

208. He LH, Ren LF, Li JF, Wu YN, Li X, Zhang L. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Front Microbiol. 2020 Jun 9;11:1388. doi: 10.3389/fmicb.2020.01388.

209. Saville S., Ouwehand A. Immune Impacts of Probiotics, Prebiotics and Synbiotics. International Probiotics Association (IPA) Education and Communications Committee. Available at: http://internationalprobiotics.org/immune/ [Accessed 10 August 2020].

210. ISAPP board of directors. How some probiotic scientists are working to address COVID-19. Available at: https://isappscience.org/how-some-probiotic-and-prebiotic-scientists-are-working-to-address-covid-19/ [Accessed 10 August 2020].

211. Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-8716. doi: 10.3748/wjg.v20.i26.8709.

212. Белова Г. В. Рекомендации по эндоскопии и клинической практике в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2020;(5):4-7. DOI: 10.31146/1682-8658-ecg-177-5-4-7

213. Парфенов А. И., Ручкина И. Н., Атауллаханов Р. И., Белая О. Ф., Чикунова Б. З., Пичугин А. В., Кожемякина Е. Ш. Постинфекционный синдром раздраженного кишечника. Терапевтический архив 2009; 81(2): 39-45.

214. Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med (Lausanne). 2020 Jun 5;7:292. doi: 10.3389/fmed.2020.00292.